Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial compared two eye drop medicines — loteprednol etabonate and prednisolone acetate — in people who had inflammation inside the eye (specifically in a fluid-filled area at the front of the eye called the anterior chamber). A total of 107 people started the trial: 54 in the loteprednol etabonate group and 53 in the prednisolone acetate group. Of those, 40 and 43 people respectively completed the study. The reported data shows that the main thing being measured was the level of inflammation in the front of the eye, scored on a scale from 0 (no inflammation) to 4 (very severe inflammation). At the end of the study, the loteprednol etabonate group had an average score of 0.913, while the prednisolone acetate group had an average score of 0.783. A second measurement looked at something called "flare" — this refers to how much a beam of light scatters when shone into the eye, which is another way of detecting inflammation. That was also scored from 0 to 4. The reported data shows the loteprednol etabonate group had an average flare score of 0.192, compared with 0.341 for the prednisolone acetate group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Children who are scheduled for a straightforward, routine cataract surgery (surgery to remove a cloudy lens in the eye)
Who may not be able to join:
- Children who have a serious eye condition, or any other unstable health condition that the doctor believes could interfere with the treatment or follow-up visits
- Children who have glaucoma, high pressure in the eye, or who are currently using any medication (eye drops or otherwise) to lower eye pressure
- Children who have previously had a rise in eye pressure caused by steroid medications
- Children who are known to be allergic to, or cannot take, the study drug or any of its ingredients
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Anterior Chamber Inflammation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.